Partner With Us NRI

SEC recommend EUA for Molnupiravir

News: Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to manufacture and market anti-Covid pill Molnupiravir for restricted emergency use for treatment of adult patients with Covid-19 in India.

Views: Merck has voluntary licensing agreements with Aurobindo, Cipla, Dr Reddy’s, Emcure, Hetero Labs, Sun Pharma, Torrent Pharma and Viatris for the drug to be manufactured and marketed in India while Divi's remains the API supplier. With rising Covid cases amid Omicron, Molnupiravir is likely to bring additional Covid revenue for Indian formulation companies.

Impact: Positive